Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients (2021)
- Authors:
- Autor USP: TRAINA, FABÍOLA - FMRP
- Unidade: FMRP
- DOI: 10.1182/blood-2021-151077
- Subjects: DOENÇAS INFECCIOSAS; FEBRE; DENGUE; ESTUDOS SOROEPIDEMIOLÓGICOS; RESÍDUOS SÓLIDOS
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2021
- Source:
- Conference titles: ASH Annual Meeting
- Status:
- Nenhuma versão em acesso aberto identificada
-
ABNT
CAMPOS, Paula de Melo et al. Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2021-151077. Acesso em: 14 abr. 2026. , 2021 -
APA
Campos, P. de M., Pagnano, K. B., Mancuso, R. I., Della Via, F. I., Tinoco, Â. C., Mendonça, G. R. A., et al. (2021). Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2021-151077 -
NLM
Campos P de M, Pagnano KB, Mancuso RI, Della Via FI, Tinoco ÂC, Mendonça GRA, Freitas LLL, Traina F, Saad STO. Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients [Internet]. Blood. 2021 ; 138 2584-2585.[citado 2026 abr. 14 ] Available from: https://doi.org/10.1182/blood-2021-151077 -
Vancouver
Campos P de M, Pagnano KB, Mancuso RI, Della Via FI, Tinoco ÂC, Mendonça GRA, Freitas LLL, Traina F, Saad STO. Final results of the fibromet trial: an open label phase II study to evaluate metformin effects on bone marrow fibrosis and disease progression in primary myelofibrosis patients [Internet]. Blood. 2021 ; 138 2584-2585.[citado 2026 abr. 14 ] Available from: https://doi.org/10.1182/blood-2021-151077 - Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412
- FMNL1 promotes proliferation and migration of leukemia cells
- SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype
- IRS1 (insulin receptor substrate 1)
- Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell–cell adhesion
- Padronização da investigação laboratorial de anticorpos dirigidos contra fármacos em doadores de sangue e pacientes com anemia hemolítica imune
- Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia
- IL32 expression in peripheral blood CD3+ cells from myelodysplastic syndromes patients
- Hedgehog pathway is deregulated in myelodysplastic syndrome progenitor bone marrow cells
- Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003237465.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
